Compare Heron Therapeutics Inc (HRTX) vs Zeta Global Holdings Corp (ZETA) Price & Performance

HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.

Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.

ZETA trades at $21.34, down 1.57% on the day, with a bullish technical signal from moving averages and strong analyst support (73% buy ratings). The company reported Q1 2026 earnings of $0.14 per share, beating estimates, and is pivoting toward AI infrastructure through partnerships with Palantir and OpenAI. Revenue grew to $1.30 billion in 2025, though net income remained negative at -$31.51 million.

The outlook is positive due to AI-driven growth and strategic partnerships, but risks include margin pressure and integration challenges. The consensus price target of $27.50 suggests significant upside potential if execution aligns with bullish expectations, though negative profitability metrics warrant caution.